Peregrine Capital Management LLC purchased a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 748,487 shares of the medical instruments supplier’s stock, valued at approximately $12,133,000. Peregrine Capital Management LLC owned approximately 2.04% of AngioDynamics as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of ANGO. Russell Investments Group Ltd. boosted its position in AngioDynamics by 5.7% in the first quarter. Russell Investments Group Ltd. now owns 315,863 shares of the medical instruments supplier’s stock valued at $5,480,000 after buying an additional 17,044 shares in the last quarter. Sawgrass Asset Management LLC purchased a new position in AngioDynamics during the first quarter valued at $282,000. Perkins Capital Management Inc. boosted its position in AngioDynamics by 5.8% in the first quarter. Perkins Capital Management Inc. now owns 54,850 shares of the medical instruments supplier’s stock valued at $952,000 after buying an additional 3,000 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in AngioDynamics by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 13,000 shares of the medical instruments supplier’s stock valued at $226,000 after buying an additional 300 shares in the last quarter. Finally, Fenimore Asset Management Inc. purchased a new position in AngioDynamics during the first quarter valued at $9,214,000. 89.19% of the stock is owned by institutional investors.
AngioDynamics, Inc. (ANGO) traded up 1.56% during trading on Wednesday, reaching $16.90. 219,839 shares of the company’s stock were exchanged. The firm has a market cap of $618.20 million, a price-to-earnings ratio of 123.36 and a beta of 1.15. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.18. The firm’s 50-day moving average price is $16.25 and its 200-day moving average price is $16.17.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.03. The firm had revenue of $86.90 million during the quarter, compared to the consensus estimate of $90.72 million. AngioDynamics had a return on equity of 5.19% and a net margin of 2.00%. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.19 EPS. On average, equities research analysts anticipate that AngioDynamics, Inc. will post $0.67 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://stocknewstimes.com/2017/08/16/peregrine-capital-management-llc-invests-12-13-million-in-angiodynamics-inc-nasdaqango-updated-updated-updated.html.
Several equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday. Cantor Fitzgerald raised their target price on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Barclays PLC decreased their target price on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 19th. Canaccord Genuity reissued a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Tuesday, July 18th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $18.50.
In other news, CEO James C. Clemmer purchased 20,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was bought at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the purchase, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Clemmer purchased 5,000 shares of the business’s stock in a transaction dated Friday, July 21st. The shares were purchased at an average price of $15.79 per share, with a total value of $78,950.00. Following the purchase, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders acquired a total of 25,316 shares of company stock valued at $396,806 in the last 90 days. Corporate insiders own 1.88% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
